Works council threatens to scupper Bayer merger

Williams, Dede; Gibson, Jane
March 2007
ICIS Chemical Business;3/12/2007, Vol. 2 Issue 57, p12
Trade Publication
The article reports that the works council at Bayer Schering Pharma has threatened to end the integration of the two formerly independent companies, Bayer and Schering, in protest of over 6,100 planned job cuts. The council is demanding a staff meeting before March 13, 2007. Berlin, Germany Mayor Klaus Wowereit appealed to Bayer to trim jobs in a socially responsible manner.


Related Articles

  • Europe Watch.  // ICIS Chemical Business;3/26/2007, Vol. 2 Issue 59, p10 

    The article reports that pharmaceutical firm Bayer has reached agreement with the works council at the new Bayer Schering Pharma on a socially acceptable plan for implementing the planned 6,100 merger-related job cuts. Employee representatives had threatened to torpedo the integration of the two...

  • NICE recommends all patients admitted to hospital are risk assessed for VTE.  // Operating Theatre Journal;Feb2010, Issue 233, p3 

    The article announces the launching of Bayer Schering Pharma AG with its implementation toolkit for the prevention of Venous Thromboembolism (VTE) in Great Britain.

  • Healthcare: Ethical Bayer Australia.  // Media: Asia's Media & Marketing Newspaper;11/19/2009, p33 

    The article reports on the use of public relations (PR) by Bayer Schering Pharma AG (BSP) as the main marketing platform to launch its oral contraceptives in Australia in 2009.

  • BiTE Advances to Preclinical Studies.  // Drug Discovery & Development;Nov2010, Vol. 13 Issue 9, p23 

    The article reports on the plans of Micromet Inc. to advance its BiTE antibody MT112/BAY2010112 into formal preclinical development in collaboration with Bayer Schering Pharma AG.

  • New progestins eyed for contraception in U.S.  // Contraceptive Technology Update;Aug2009, Vol. 30 Issue 8, p89 

    The article reports on the clinical trials conducted by biopharmaceutical company Bayer Schering Pharma AG on the use of contraceptive progestins using ethinyl estradiol and gestodene among women in the U.S.

  • Bayer Schering Bites on BiTE Option for Micromet Antibody.  // BioWorld Today;12/2/2009, Vol. 20 Issue 231, p2 

    The article reprots that Micromet Inc. will be given 7.5 million U.S. dollars and future milestone payments following the decision of Bayer Schering Pharma AG to develop a preclinical BiTE antibody for cancer.

  • ExL Pharma's Leading European Digital Marketing & PR Conference to be Hosted @ Bayer Schering.  // Biomedical Market Newsletter;5/12/2011, p146 

    The article offers information on the Second Annual Digital Pharma Europe and European Public Relations & Communications Summit to be hosted by Bayer Schering Pharma AG on March 29 to 30, 2010 in Berlin, Germany.

  • Estimating the domain of applicability for machine learning QSAR models: a study on aqueous solubility of drug discovery molecules. Schroeter, Timon Sebastian; Schwaighofer, Anton; Mika, Sebastian; Ter Laak, Antonius; Suelzle, Detlev; Ganzer, Ursula; Heinrich, Nikolaus; M�ller, Klaus-Robert // Journal of Computer-Aided Molecular Design;Sep2007, Vol. 21 Issue 9, p485 

    We investigate the use of different Machine Learning methods to construct models for aqueous solubility. Models are based on about 4000 compounds, including an in-house set of 632 drug discovery molecules of Bayer Schering Pharma. For each method, we also consider an appropriate method to obtain...

  • Micromet, Bayer Schering Sign Preclinical BiTE Antibody Deal. Boggs, Jennifer // BioWorld Today;1/13/2009, Vol. 20 Issue 7, p1 

    The article reports on a deal signed between Micromet Inc. and German pharma firm Bayer Schering AG that will grant Bayer a one-year option to a preclinical Bispecific T-Cell Engager (BiTE) antibody for cancer. In exchange, Micromet will receive €4.5 million. Micromet has also had...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics